|
1
|
Jemal A, Center MM, DeSantis C and Ward
EM: Global patterns of cancer incidence and mortality rates and
trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hubbert C, Guardiola A, Shao R, Kawaguchi
Y, Ito A, Nixon A, Yoshida M, Wang XF and Yao TP: HDAC6 is a
micro-tubule-associated deacetylase. Nature. 417:455–458. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang Y, Gilquin B, Khochbin S and
Matthias P: Two catalytic domains are required for protein
deacetylation. J Biol Chem. 281:2401–2404. 2006. View Article : Google Scholar
|
|
5
|
Li Y, Shin D and Kwon SH: Histone
deacetylase 6 plays a role as a distinct regulator of diverse
cellular processes. FEBS J. 280:775–793. 2013.
|
|
6
|
Boyault C, Zhang Y, Fritah S, Caron C,
Gilquin B, Kwon SH, Garrido C, Yao TP, Vourc'h C, Matthias P, et
al: HDAC6 controls major cell response pathways to cytotoxic
accumulation of protein aggregates. Genes Dev. 21:2172–2181. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kawaguchi Y, Kovacs JJ, McLaurin A, Vance
JM, Ito A and Yao TP: The deacetylase HDAC6 regulates aggresome
formation and cell viability in response to misfolded protein
stress. Cell. 115:727–738. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kwon S, Zhang Y and Matthias P: The
deacetylase HDAC6 is a novel critical component of stress granules
involved in the stress response. Genes Dev. 21:3381–3394. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang Y, Kwon S, Yamaguchi T, Cubizolles
F, Rousseaux S, Kneissel M, Cao C, Li N, Cheng HL, Chua K, et al:
Mice lacking histone deacetylase 6 have hyperacetylated tubulin but
are viable and develop normally. Mol Cell Biol. 28:1688–1701. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bergman JA, Woan K, Perez-Villarroel P,
Villagra A, Sotomayor EM and Kozikowski AP: Selective histone
deacetylase 6 inhibitors bearing substituted urea linkers inhibit
melanoma cell growth. J Med Chem. 55:9891–9899. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Butler LM, Agus DB, Scher HI, Higgins B,
Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA and Richon
VM: Suberoylanilide hydroxamic acid, an inhibitor of histone
deacetylase, suppresses the growth of prostate cancer cells in
vitro and in vivo. Cancer Res. 60:5165–5170. 2000.PubMed/NCBI
|
|
12
|
Inks ES, Josey BJ, Jesinkey SR and Chou
CJ: A novel class of small molecule inhibitors of HDAC6. ACS Chem
Biol. 7:331–339. 2012. View Article : Google Scholar :
|
|
13
|
Santo L, Hideshima T, Kung AL, Tseng JC,
Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, et
al: Preclinical activity, pharmacodynamic, and pharmacokinetic
properties of a selective HDAC6 inhibitor, ACY-1215, in combination
with bortezomib in multiple myeloma. Blood. 119:2579–2589. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smil DV, Manku S, Chantigny YA, Leit S,
Wahhab A, Yan TP, Fournel M, Maroun C, Li Z, Lemieux AM, et al:
Novel HDAC6 isoform selective chiral small molecule histone
deacetylase inhibitors. Bioorg Med Chem Lett. 19:688–692. 2009.
View Article : Google Scholar
|
|
15
|
Estiu G, Greenberg E, Harrison CB,
Kwiatkowski NP, Mazitschek R, Bradner JE and Wiest O: Structural
origin of selectivity in class II-selective histone deacetylase
inhibitors. J Med Chem. 51:2898–2906. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Haggarty SJ, Koeller KM, Wong JC,
Grozinger CM and Schreiber SL: Domain-selective small-molecule
inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin
deacetylation. Proc Natl Acad Sci USA. 100:4389–4394. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dallavalle S, Pisano C and Zunino F:
Development and therapeutic impact of HDAC6-selective inhibitors.
Biochem Pharmacol. 84:756–765. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ashjian E and Redic K: Multiple myeloma:
Updates for pharmacists in the treatment of relapsed and refractory
disease. J Oncol Pharm Pract. 22:289–302. 2016. View Article : Google Scholar
|
|
19
|
Vogl DT, Raje N, Jagannath S, Richardson
P, Hari P, Orlowski R, Supko JG, Tamang D, Yang M, Jones SS, et al:
Ricolinostat, the first selective histone deacetylase 6 inhibitor,
in combination with bortezomib and dexamethasone for relapsed or
refractory multiple myeloma. Clin Cancer Res. 23:3307–3315. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yee AJ, Bensinger WI, Supko JG, Voorhees
PM, Berdeja JG, Richardson PG, Libby EN, Wallace EE, Birrer NE,
Burke JN, et al: Ricolinostat plus lenalidomide, and dexamethasone
in relapsed or refractory multiple myeloma: A multicentre phase 1b
trial. Lancet Oncol. 17:1569–1578. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dasmahapatra G, Patel H, Friedberg J,
Quayle SN, Jones SS and Grant S: In vitro and in vivo interactions
between the HDAC6 inhibitor ricolinostat (ACY1215) and the
irreversible proteasome inhibitor carfilzomib in non-Hodgkin
lymphoma cells. Mol Cancer Ther. 13:2886–2897. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Witter DJ, Harrington P, Wilson KJ,
Chenard M, Fleming JC, Haines B, Kral AM, Secrist JP and Miller TA:
Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
Bioorg Med Chem Lett. 18:726–731. 2008. View Article : Google Scholar
|
|
24
|
Hideshima T, Cottini F, Ohguchi H,
Jakubikova J, Gorgun G, Mimura N, Tai YT, Munshi NC, Richardson PG
and Anderson KC: Rational combination treatment with histone
deacetylase inhibitors and immunomodulatory drugs in multiple
myeloma. Blood Cancer J. 5:e3122015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mishima Y, Santo L, Eda H, Cirstea D,
Nemani N, Yee AJ, O'Donnell E, Selig MK, Quayle SN, Arastu-Kapur S,
et al: Ricolinostat (ACY-1215) induced inhibition of aggresome
formation accelerates carfilzomib-induced multiple myeloma cell
death. Br J Haematol. 169:423–434. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Quayle SN and Jones SS: ACY-1215, a
first-in-class selective inhibitor of HDAC6, demonstrates
significant synergy with immunomodulatory drugs (IMiDs) in
preclinical models of multiple myeloma (MM). Blood.
122:19522013.
|
|
27
|
Ryu HW, Shin DH, Lee DH, Won HR and Kwon
SH: A potent hydroxamic acid-based, small-molecule inhibitor A452
preferentially inhibits HDAC6 activity and induces cytotoxicity
toward cancer cells irrespective of p53 status. Carcinogenesis.
39:72–83. 2018. View Article : Google Scholar
|
|
28
|
Falkenberg KJ and Johnstone RW: Histone
deacetylases and their inhibitors in cancer, neurological diseases
and immune disorders. Nat Rev Drug Discov. 13:673–691. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Marks PA and Xu WS: Histone deacetylase
inhibitors: Potential in cancer therapy. J Cell Biochem.
107:600–608. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bruserud O, Stapnes C, Ersvaer E, Gjertsen
BT and Ryningen A: Histone deacetylase inhibitors in cancer
treatment: A review of the clinical toxicity and the modulation of
gene expression in cancer cell. Curr Pharm Biotechnol. 8:388–400.
2007. View Article : Google Scholar
|
|
31
|
Kaliszczak M, Trousil S, Åberg O, Perumal
M, Nguyen QD and Aboagye EO: A novel small molecule hydroxamate
preferentially inhibits HDAC6 activity and tumour growth. Br J
Cancer. 108:342–350. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Alzoubi S, Brody L, Rahman S,
Mahul-Mellier AL, Mercado N, Ito K, El-Bahrawy M, Silver A, Boobis
A, Bell JD, et al: Synergy between histone deacetylase inhibitors
and DNA-damaging agents is mediated by histone deacetylase 2 in
colorectal cancer. Oncotarget. 7:44505–44521. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Flis S, Gnyszka A and Spławiński J: HDAC
inhibitors, MS275 and SBHA, enhances cytotoxicity induced by
oxaliplatin in the colorectal cancer cell lines. Biochem Biophys
Res Commun. 387:336–341. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang Z, Hu P, Tang F, Lian H, Chen X,
Zhang Y, He X, Liu W and Xie C: HDAC6 promotes cell proliferation
and confers resistance to temozolomide in glioblastoma. Cancer
Lett. 379:134–142. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang P, Almeciga-Pinto I, Jarpe M, van
Duzer JH, Mazitschek R, Yang M, Jones SS and Quayle SN: Selective
HDAC inhibition by ACY-241 enhances the activity of paclitaxel in
solid tumor models. Oncotarget. 8:2694–2707. 2017.
|
